Sevilla

• A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon) Ended
  2022-501538-44-00 5 2023-04-25 Atopic Dermatitis
• A study to test if izokibep improves psoriatic arthritis symptoms and to see how safe izokibep is Ended
  2022-501362-22-00 10 2023-04-18 Psoriatic Arthritis
• A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended
  2022-501259-10-00 4 2023-04-14 Relapsed/Refractory Waldenstrom Macroglobulinemia (WM)
• A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended
  2022-501260-18-00 4 2023-04-14 Relapsed/refractory Richter Transformation (RT)
• A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancie … Ended
  2022-501261-46-00 4 2023-04-14 Relapsed/Refractory Burkitt Lymphoma (BL)
• A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended
  2022-501262-21-00 4 2023-04-14 Relapsed/Refractory Hairy Cell Leukemia
• A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy Ended
  2023-506352-24-00 5 2023-04-13 Non-obstructive Hypertrophic Cardiomyopathy
• A Study of Peresolimab (LY3462817) in Adults Participants With Moderately-to-Severely Active Rheumatoid Arthritis Ended
  2022-501425-20-00 4 2023-04-03 Rheumatoid Arthritis Arthritis Joint Diseases Musculoskeletal Disea
• A Phase Ib/II, Multi-Center, Open-Label Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH925 in Combination w … Ended
  2022-501451-87-00 9 2023-03-31 Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation
• Phase 2b Study of GSK4532990 in Adults with NASH (HORIZON) Ended
  2023-507503-62-00 4 2023-03-30 Non-alcoholic Fatty Liver Disease
• A Study of LY3540378 in Participants with Worsening Chronic Heart Failure with Preserved Ejection Fraction (HFpEF) Ended
  2023-505902-40-00 4 2023-03-28 Heart Failure with Preserved Ejection Fraction
• A Phase 1 Study of the SHP2 Inhibitor BBP-398 (formerly known as IACS-15509) in combination with the KRAS-G12C Inhibitor Sotorasib in Patien … Ended
  2022-501363-40-00 3 2023-03-17 Advanced or metastatic solid tumors with a KRAS-G12C mutation
• OMX-0407 Phase I Study Ended
  2024-514554-75-00 1 2023-03-16 Previously treated unresectable solid tumours
• C4951004 - BHV3000-406: A Phase 4, Randomized, Double-blind Placebo Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute … Ended
  2024-513269-37-00 6 2023-03-14 Migraine attacks with or without aura
• C4951012 - BHV3000-407: A Phase 4, Randomized, Double-blind, Placebo controlled Study to Evaluate the Efficacy and Tolerability of Rimegepan … Ended
  2024-513270-21-00 6 2023-03-14 migraine headaches with or without aura
• Single arm phase II study of the efficacy and safety of the combination of Trastuzumab plus TUCAtinib plus viNorelbine in patients with HER2 … Ended
  2024-512590-27-00 9 2023-03-08 Non-resectable locally advanced or metastatic HER2-positive breast can
• Prophylaxis of venous thromboembolic disease with LMWH (TINzaparin) in patients with metastatic colorectal cancer who start the first line o … Ended
  2023-508860-31-00 5 2023-02-28 Stage IV colon or rectal adenocarcinoma (mCRC).
• A Open-label Study to Evaluate the Efficacy, Safety, Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis Ended
  2023-509783-23-00 4 2023-02-24 Diffuse Cutaneous Systemic Sclerosis
• First-in-human phase I/IIa study investigating inhaled CIS-DPI as add-on treatment in Stage IV NSCLC patients Ended
  2022-501183-17-00 7 2023-02-23 Non-Small Cell Lung Cancer
• A trial in patients with blood cancer and lymphatic system cancer looking at finding the optimal dose of BMF-219 Ended
  2024-515744-23-00 1 2023-02-15 Relapsed or refractory (R/R) Acute lymphoblastic leukemia (ALL), R/R A
• A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)] Ended
  2022-501426-38-00 4 2023-02-09 Lipoprotein Disorder
• A clinical study to evaluate mRNA-3705 in Patients with MMA Ended
  2022-502492-32-00 7 2023-02-03 Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Defici
• A proof-of-concept study to examine QUC398 in participants with knee osteoarthritis Ended
  2023-509274-28-00 4 2023-02-03 Knee osteoarthritis
• Multicenter, Open-label, Single arm, Phase II Clinical Trial to Improve Sacituzumab Govitecan Tolerance in Patients with Metastatic Triple-N … Ended
  2024-514060-10-00 4 2023-02-02 Advanced triple-negative breast cancer (TNBC), Advanced HR[+]/HER2[–]

Showing 1,393–1,416 of 1,630 trials